ALK and non-small cell lung carcinoma: We performed a network meta-analysis of frontline treatment options of ALK-positive NSCLC to provide clinical guidance.<h4>Methods</h4>PubMed, Embase, ClinicalTrials.gov, and international conference databases were searched to identify relevant trials from inception to June 30, 2021.